Mumbai, India (CU)_ Beroni Group, an international biopharmaceutical business headquartered in New South Wales, Australia, announced that PENAO Pty Ltd, its majority-owned anti-cancer medication development company in Sydney, has inked a drug production agreement with Aurigene Pharmaceutical Services, India, which is an affiliate of Dr. Reddy’s Laboratories. Beroni Group presently runs four major businesses namely, cell treatments, the development of novel anti-cancer medicines, the e-commerce platform for pharmaceutical and healthcare items, and the detection and diagnosis of infectious illnesses. The overarching mission of the company is to emerge as the world’s top business in the areas of biotechnology, life sciences, and environmental science.
In a phase I clinical trial carried out in Australia, PENAO, next-generation adenine nucleotide translocase (ANT) inhibitor, was found to be safe and well-tolerated, with promising effective results. PENAO injections will be given twice in a week to patients with severe solid tumors in a second clinical study set to begin in the first half of 2022. It will be a dose-finding research that will also look into anti-tumor effects utilizing morphological evaluations such as radiographic responses, molecular imaging surrogates, and anti-proliferative effects.
CEO of Beroni Group Jacky Zhang expressed optimism over the new cancer drug. He said, “I am pleased that we are making significant progress in the development of the anti-cancer drug PENAO. PENAO is a novel therapy targeting tumor cell mitochondria and could potentially have application in a wide range of cancers, including colorectal cancer, pancreatic cancer, ovarian cancer, liver cancer, etc. It is a potential treatment for cancers that are unresponsive to standard treatment, or for which no standard treatment exists.”